Ginkgo Bioworks Holdings annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Ginkgo Bioworks Holdings Stock-Based Compensation Growth & History (DNA)
Ginkgo Bioworks Holdings's stock-based compensation was $81.5M for fiscal 2025.
View full Ginkgo Bioworks Holdings company overviewGinkgo Bioworks Holdings annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $81.5M | −$30.8M | −27.41% |
| 2024 | 2024-12-31 | $112.3M | −$117.5M | −51.13% |
| 2023 | 2023-12-31 | $229.9M | −$1.70B | −88.09% |
| 2022 | 2022-12-31 | $1.93B | $324.6M | +20.21% |
| 2021 | 2021-12-31 | $1.61B | $1.61B | +337299.16% |
| 2020 | 2020-12-31 | $476,000 | −$295,000 | −38.26% |
| 2019 | 2019-12-31 | $771,000 | — | — |
Ginkgo Bioworks Holdings quarterly stock-based compensation
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7.6M | −$11.2M | −59.61% |
| Q1 2026 | 2026-03-31 | $15.9M | −$1.5M | −8.82% |
| Q4 2025 | 2025-12-31 | $21.0M | $466,000 | +2.27% |
| Q3 2025 | 2025-09-30 | $24.3M | $10.5M | +75.60% |
| Q2 2025 | 2025-06-30 | $18.8M | −$18.3M | −49.38% |
| Q1 2025 | 2025-03-31 | $17.4M | −$23.4M | −57.37% |
| Q4 2024 | 2024-12-31 | $20.6M | −$22.3M | −52.00% |
| Q3 2024 | 2024-09-30 | $13.9M | −$38.7M | −73.65% |
| Q2 2024 | 2024-06-30 | $37.1M | −$24.3M | −39.59% |
| Q1 2024 | 2024-03-31 | $40.8M | −$32.2M | −44.12% |
| Q4 2023 | 2023-12-31 | $42.8M | −$65.3M | −60.40% |
| Q3 2023 | 2023-09-30 | $52.6M | −$510.6M | −90.66% |
| Q2 2023 | 2023-06-30 | $61.5M | −$545.0M | −89.86% |
| Q1 2023 | 2023-03-31 | $73.0M | −$579.8M | −88.82% |
| Q4 2022 | 2022-12-31 | $108.2M | −$1.48B | −93.20% |
| Q3 2022 | 2022-09-30 | $563.1M | $563.0M | +443314.17% |
| Q2 2022 | 2022-06-30 | $606.5M | $592.0M | +4077.39% |
| Q1 2022 | 2022-03-31 | $652.8M | $652.7M | +553138.14% |
| Q4 2021 | 2021-12-31 | $1.59B | — | — |
| Q3 2021 | 2021-09-30 | $127,000 | $9,000 | +7.63% |
| Q2 2021 | 2021-06-30 | $14.5M | — | — |
| Q1 2021 | 2021-03-31 | $118,000 | — | — |
| Q3 2020 | 2020-09-30 | $118,000 | — | — |
Ginkgo Bioworks Holdings stock-based compensation trends
Over the last five fiscal years, Ginkgo Bioworks Holdings's stock-based compensation increased from $476,000 to $81.5M, a change of $81.1M. The latest reported quarter, Q2 2026, shows $7.6M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ginkgo Bioworks Holdings source filings ↗Community posts
Ginkgo joins a federally backed RNA-manufacturing project worth up to $17.5 million
Ginkgo Bioworks ($DNA) received a subcontract worth up to $17.5 million to participate in an ARPA-H program focused on RNA manufacturing. Waterfall Scientific is the prime contractor. The project, called ESCALATOR, is intended to combine co ...